E5 monoclonal antibody: XOMA and partner Pfizer (New York, N.Y.) halted their third Phase III trial for sepsis after an interim review by an institutional revie

(IND withdrawn temporarily, see Clinical Status.)

Xoma Corp. (XOMA), Berkeley,

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE